All Relations between asymmetrical (pato 0000616) and nitrogen monoxide

Reference Sentence Publish Date Extraction Date Species
E Arikan, C H Karadag, S Guldike. Asymmetric dimethylarginine levels in thyroid diseases. Journal of endocrinological investigation vol 30 issue 3 2007 17505150 asymmetric dimethylarginine (adma), a novel inhibitor of endothelial nitric oxide synthase (enos), blocks nitric oxide (no) synthesis from l-arginine. 2007-07-10 2022-01-12 Not clear
Marieke O Verhoeven, Tom Teerlink, Peter Kenemans, Tatjana E Vogelvang, Marius J van der Moore. Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. Menopause (New York, N.Y.) vol 14 issue 2 2007 17146377 to investigate the short-term effects of three different doses of the selective estrogen receptor modulator hmr 3339 in comparison with placebo and raloxifene on asymmetric dimethylarginine (adma), a nitric oxide synthase inhibitor. 2007-06-21 2022-01-12 Not clear
Bin Tan, De-Jian Jiang, Huang Huang, Su-Jie Jia, Jun-Lin Jiang, Chang-Ping Hu, Yuan-Jian L. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway. Vascular pharmacology vol 46 issue 5 2007 17293168 asymmetric dimethylarginine (adma), a major endogenous nitric oxide (no) synthase inhibitor, is thought to be a key contributor for endothelial dysfunction. 2007-05-29 2022-01-12 Not clear
Renke Maas, Friedrich Schulze, Jens Baumert, Hannelore L\\xc3\\xb6wel, Khatera Hamraz, Edzard Schwedhelm, Wolfgang Koenig, Rainer H B\\xc3\\xb6ge. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clinical chemistry vol 53 issue 4 2007 17317881 an increased plasma concentration of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (adma) predicts adverse clinical outcome in patients with coronary heart disease. 2007-05-21 2022-01-13 Not clear
Necip Ilhan, Dilara Seckin, Nevin Ilhan, Yilmaz Ozba. Abnormal asymmetric dimethylarginine/nitric oxide balance in patients with documented coronary artery disease: relation to renal function and homocysteine. Journal of thrombosis and thrombolysis vol 23 issue 3 2007 17160550 as an endogenous inhibitor of nitric oxide production, asymmetric dimethylarginine (adma) is reported to be associated with coronary artery disease (cad). 2007-05-16 2022-01-12 Not clear
F Mittermayer, A Kautzky-Willer, C Winzer, K Krzyzanowska, T Prikoszovich, S Demehri, O Wagner, M Wolz. Elevated concentrations of asymmetric dimethylarginine are associated with deterioration of glucose tolerance in women with previous gestational diabetes mellitus. Journal of internal medicine vol 261 issue 4 2007 17391114 the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (adma) could be related to disorders of the glucose metabolism. 2007-05-10 2022-01-12 Not clear
Rajeshwar P Mookerjee, R Neil Dalton, Nathan A Davies, Stephen J Hodges, Charles Turner, Roger Williams, Rajiv Jala. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society vol 13 issue 3 2007 17318866 inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (adma) in acute liver failure. 2007-05-08 2022-01-13 Not clear
Rajeshwar P Mookerjee, R Neil Dalton, Nathan A Davies, Stephen J Hodges, Charles Turner, Roger Williams, Rajiv Jala. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society vol 13 issue 3 2007 17318866 asymmetric dimethylarginine (adma), an endogenous nitric oxide synthase inhibitor, results from proteolysis and the liver is a major site for its metabolism. 2007-05-08 2022-01-13 Not clear
Vito De Gennaro Colonna, Sara Bonomo, Paolo Ferrario, Mauro Bianchi, Marco Berti, Marco Guazzi, Barbara Manfredi, Eugenio E Muller, Ferruccio Berti, Giuseppe Rosson. Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats. European journal of pharmacology vol 557 issue 2-3 2007 17258196 asymmetric dimethylarginine (adma) is an endogenous nitric oxide (no) inhibitor recognized as an independent risk factor for endothelial dysfunction and coronary heart diseases. 2007-05-04 2022-01-12 Not clear
James Leiper, Manasi Nandi, Belen Torondel, Judith Murray-Rust, Mohammed Malaki, Bernard O'Hara, Sharon Rossiter, Shelagh Anthony, Melanie Madhani, David Selwood, Caroline Smith, Beata Wojciak-Stothard, Alain Rudiger, Ray Stidwill, Neil Q McDonald, Patrick Vallanc. Disruption of methylarginine metabolism impairs vascular homeostasis. Nature medicine vol 13 issue 2 2007 17273169 asymmetric dimethylarginine (adma) and monomethyl arginine (l-nmma) are endogenously produced amino acids that inhibit all three isoforms of nitric oxide synthase (nos). 2007-04-30 2022-01-12 Not clear
Zhi-Chun Yang, Ke Xia, Li Wang, Su-Jie Jia, Dai Li, Zhe Zhang, Shen Deng, Xiao-Hong Zhang, Han-Wu Deng, Yuan-Jian L. Asymmetric dimethylarginine reduced erythrocyte deformability in streptozotocin-induced diabetic rats. Microvascular research vol 73 issue 2 2007 17098259 after incubation of erythrocytes with asymmetric dimethylarginine (10(-6) m) for 30 min, erythrocyte deformability and nitric oxide level in erythrocytes were decreased markedly. 2007-04-24 2022-01-12 Not clear
Zhi-Chun Yang, Ke Xia, Li Wang, Su-Jie Jia, Dai Li, Zhe Zhang, Shen Deng, Xiao-Hong Zhang, Han-Wu Deng, Yuan-Jian L. Asymmetric dimethylarginine reduced erythrocyte deformability in streptozotocin-induced diabetic rats. Microvascular research vol 73 issue 2 2007 17098259 these results indicated that reduction of erythrocyte deformability in diabetic rats was associated with promoted oxidant stress as well as impaired nitric oxide synthesis by elevation of asymmetric dimethylarginine. 2007-04-24 2022-01-12 Not clear
Andrzej Surdacki, Jens Martens-Lobenhoffer, Alicja Wloch, Ewa Marewicz, Tomasz Rakowski, Ewa Wieczorek-Surdacka, Jacek S Dubiel, Juliusz Pryjma, Stefanie M Bode-B\\xc3\\xb6ge. Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis and rheumatism vol 56 issue 3 2007 17328055 this study was undertaken to test the hypothesis that endothelial progenitor cell depletion and subclinical atherosclerosis in ra may be related to accumulation of an endogenous inhibitor of nitric oxide (no) synthesis, asymmetric dimethyl-l-arginine. 2007-04-12 2022-01-13 Not clear
Kumiko Furuki, Hisashi Adachi, Hidehiro Matsuoka, Mika Enomoto, Akira Satoh, Asuka Hino, Yuji Hirai, Tsutomu Imaizum. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis vol 191 issue 1 2007 16672157 asymmetric dimethylarginine (adma) is a circulating endogenous nitric oxide (no) synthase inhibitor. 2007-04-10 2022-01-12 Not clear
Elena Monsalve, Pilar J Oviedo, Miguel Angel Garc\\xc3\\xada-P\\xc3\\xa9rez, Juan J Tar\\xc3\\xadn, Antonio Cano, Carlos Hermenegild. Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells. Cardiovascular research vol 73 issue 1 2007 17097077 asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide (no) synthase, is a novel cardiovascular risk factor produced by endothelial cells. 2007-04-10 2022-01-12 Not clear
Doan T M Ngo, Tamila Heresztyn, Kumaril Mishra, Thomas H Marwick, John D Horowit. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA). Nitric oxide : biology and chemistry vol 16 issue 2 2007 17126043 we tested the hypothesis that the presence of aortic stenosis (as) is associated with elevation of plasma levels of asymmetric dimethylarginine (adma), a physiological inhibitor of nitric oxide synthase, a mediator and marker of endothelial dysfunction and an indicator of incremental cardiovascular risk. 2007-04-10 2022-01-12 Not clear
Narbeh Melikian, Stephen B Wheatcroft, Okechukwu S Ogah, Cliona Murphy, Phillip J Chowienczyk, Anthony S Wierzbicki, Thomas A B Sanders, Benyu Jiang, Edward R Duncan, Ajay M Shah, Mark T Kearne. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension (Dallas, Tex. : 1979) vol 49 issue 4 2007 17261643 asymmetric dimethylarginine and reduced nitric oxide bioavailability in young black african men. 2007-04-05 2022-01-12 Not clear
Wei-ru Zhang, Fan-fan Hou, Jian-ping Ning, Xiao-bing Yang, Qiang Wu, Li-jian Tao, Ben-mei Chen, Hong-yan Li, Lan Chan. Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences vol 31 issue 5 2007 17062918 to determine the association between asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide (no) synthase, with atherosclerosis in patients with chronic kidney disease (ckd). 2007-03-29 2022-01-12 Not clear
Jun-Lin Jiang, Xiao-Hong Zhang, Nian-Sheng Li, Wei-Qing Rang, Feng-Ye, Chang-Ping Hu, Yuan-Jian Li, Han-Wu Den. Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase I and dimethylarginine dimethylaminohydrolase activity. Cardiovascular drugs and therapy vol 20 issue 4 2007 16897158 asymmetric dimethylarginine (adma), an endogenous nitric oxide synthase inhibitor (nos), may play an important role in endothelium dysfunction. 2007-03-21 2022-01-12 Not clear
P Wanby, I Nilsson, L Brudin, I Nyhammar, I Gustafsson, M Carlsso. Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. Acta neurologica Scandinavica vol 115 issue 2 2007 17212611 both asymmetric dimethylarginine (adma), which is an inhibitor of endothelial nitric oxide synthase and the fatty acid-binding protein 2 (fabp2) a54t gene polymorphism have been associated with cerebrovascular disease. 2007-03-20 2022-01-12 Not clear
Page: 
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36   37   38   39   40   41   42   43   44   45   46   47   48   49   50   51   52   53   54